Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...

HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...

Please provide your email address to receive an email when new articles are posted on . Young children with type 1 diabetes had similar glycemic outcomes using fast-acting insulin aspart vs. standard ...

Expert Rev Endocrinol Metab. 2010;5(4):507-516. The 'Summary of Product Characteristics' for BIAsp 30 has recently been changed to reflect data from the clinical trial program. These data showed that ...

July 27, 2010 — The US Food and Drug Administration (FDA) has granted 510(k) clearance to market an insulin patch-pen (Finesse; Calibra Medical, Inc) for up to 3 days' use with rapid-acting insulin ...

Treating children with mild diabetic ketoacidosis (DKA) using subcutaneous (SC) insulin aspart was linked to lower hospital costs and better efficacy of DKA management, compared with using intravenous ...

The active ingredient in Fiasp is insulin aspart. (An active ingredient is what makes a drug work.) Fiasp is a biologic drug, which means it’s made from living cells. Fiasp comes as a liquid solution ...